Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | BCHE | P06276 | 1/20 | 0.51 |
| ▸ | ACHE | P22303 | 1/20 | 0.51 |
| ▸ | CDK4 | P11802 | 1/20 | 0.50 |
| ▸ | CCND1 | P24385 | 1/20 | 0.50 |
| ▸ | CES2 | O00748 | 1/20 | 0.50 |
| ▸ | CES1 | P23141 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 5/20 | 0.48 |
| ▸ | CA2 | P00918 | 5/20 | 0.48 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.47 |
| ▸ | GSK3B | P49841 | 1/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.47 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19479112 | 0.91 | DRD2 (0.74) | DRD2MEN1KMT2ABCHEACHE | |
| SCHEMBL10795881 | 0.87 | HDAC4 (0.54) | DRD2CDK4CCND1HPGDHDAC4 | |
| SCHEMBL16945939 | 0.86 | DRD2 (0.64) | DRD2MEN1KMT2ABCHEACHE | |
| SCHEMBL19479113 | 0.85 | DRD2 (0.62) | DRD2MEN1KMT2ABCHEACHE | |
| SCHEMBL6023472 | 0.84 | CES2 (0.52) | DRD2CES2CES1HPGDKDM4E | |
| SCHEMBL14175138 | 0.83 | DRD2 (0.61) | DRD2MEN1KMT2ABCHEACHE | |
| SCHEMBL19997006 | 0.83 | DRD2 (0.61) | DRD2MEN1KMT2ABCHEACHE | |
| SCHEMBL19634283 | 0.83 | ALDH1A1 (0.55) | DRD2MEN1KMT2AHPGDKDM4E | |
| SCHEMBL16941089 | 0.82 | DRD2 (0.59) | DRD2MEN1KMT2ABCHEACHE | |
| SCHEMBL7531226 | 0.81 | DRD2 (0.57) | DRD2MEN1KMT2ACES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230312511-A1 | SELECTIVE D3 DOPAMINE RECEPTOR AGONISTS AND METHODS OF THEIR USE | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2023-10-05 | — | — | US | disclosed |
| US-20230312511-A1 | SELECTIVE D3 DOPAMINE RECEPTOR AGONISTS AND METHODS OF THEIR USE | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2023-10-05 | — | — | US | disclosed |
| US-20210323941-A1 | SELECTIVE D3 DOPAMINE RECEPTOR AGONISTS AND METHODS OF THEIR USE | THE UNIVERSITY OF KANSAS | 2021-10-21 | — | — | US | disclosed |
| EP-3442955-B1 | SELECTIVE D3 DOPAMINE RECEPTOR AGONISTS AND METHODS OF THEIR USE | US HEALTH (US) | 2021-09-29 | — | — | EP | disclosed |
| WO-2017181004-A1 | SELECTIVE D3 DOPAMINE RECEPTOR AGONISTS AND METHODS OF THEIR USE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2017-10-19 | — | — | WO | disclosed |
| US-20040082774-A1 | Novel phosphate and thiophosphate protecting groups | ISIS PHARMACEUTICALS, INC. | 2004-04-29 | — | — | US | disclosed |
| US-6610837-B1 | Preparation of an oligonucleotide compound of given formula by reacting with given compounds, followed by oxidation or sulfurization | ISIS PHARMACEUTICALS, INC. | 2003-08-26 | — | — | US | disclosed |
| US-6121437-A | SYNTHESIS OF OLIGONUCLEOTIDES USING OLIGONUCLEOTIDES OR NUCLEOTIDES WITH PROTECTED INTERNUCLEOSIDIC PHOSPHORUS FUNCTIONALITIES WHICH CAN BE REMOVED UNDER MILD CONDITIONS AND PRODUCE NONTOXIC BY-PRODUCTS | ISIS PHARMACEUTICALS, INC. (US) | 2000-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210323941-A1 | SELECTIVE D3 DOPAMINE RECEPTOR AGONISTS AND METHODS OF THEIR USE | SLC6A3, DRD3, CHRM2 | DRD2 4/4885MEN1 3264/4885KMT2A 2972/4885 |
| US-20230312511-A1 | SELECTIVE D3 DOPAMINE RECEPTOR AGONISTS AND METHODS OF THEIR USE | SLC6A3, DRD3, DRD2 | DRD2 3/4885MEN1 3373/4885KMT2A 3239/4885 |
| US-20040082774-A1 | Novel phosphate and thiophosphate protecting groups | TYMP, MTAP, PPIP5K2 | DRD2 4514/4885MEN1 3835/4885KMT2A 4615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.